Trulieve Cannabis (CSE: TRUL) announced that they will be reporting their second quarter financials before the market opens on August 12.
Analysts have a consensus C$82.52 12-month price target on the company, via a total of 16 analysts, with 5 analyst having a strong buy rating, and 11 analysts have a buy rating. The street high comes from Stifel-GMP with a C$132 price target, and the lowest target comes in at a C$39.50 price target.
12 analysts have revenue estimates for the second quarter. The mean between all 12 is $208.87 million; this number has been slightly higher from $190.37 million at the start of the year. The street high is $216 million while the lowest sits at $203.30 million.
Seven analysts have estimates for what this quarter’s gross profit margin will be. They expect the profit margin to come in at 70.84%, with this number being revised upwards from 65% at the start of the year. Street high goes to Cantor Fitzgerald with a 72% estimate and the lowest sits at 69%.
Onto EBITDA estimates, there are currently 11 analysts who have second quarter EBITDA estimates. The mean is currently $93.68 million, with this number being higher than at the start of the year. Street high goes to Cantor Fitzgerald with a $101.80 million EBITDA estimate and the lowest being a $90.90 million estimate.
Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
